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Macrophage Damage in Relation to the
Pathogenesis of Lung Diseases
by Joseph D. Brain*
Pulnonary macrophages are important since their migratory patterns and behavior are often pivotal
events in the pathogenesis ofpulmonary disease. Alveolar macrophages act to decrease the probability of
particle penetration through epithelial barriers, and their phagocytic and lytic potentials provide most of
the known bactericidal properties ofthe lungs. Macrophages are also involved in immune responsesand in
defense against neoplasms. Increased inert or infectious particles stimulate the recruitment ofadditional
macrophages. Most free cells containing particles eventualy reach the airways and are quickly carried to
the pharynx and swallowed.
In addition, evidence has now accumulated that macrophages play a part in the pathogenesis of
pulmonary diseases. For example, the ingestion of some particles by macrophages causes a release of
lysosomal enzymes into the macrophage cytoplasm. Theseenzymes may kill the macrophage, and dead or
dying macrophages release a substance which attracts fibroblasts that elicit fibrogenic responses. Other
toxic particles, such as cigarette smoke, may lead to a release of proteases and other toxic enzymes. All
particles are capable ofcompetitive inhibition ofphagocytosis in macrophages and many may becytotoxic
and further depress phagocytosis. In addition, connective tissue macrophages may contribute to lung
diseasebyconcentrating andstoringpotentcarcinogens orothertoxicparticlesclosetoareactivebronchial
epitheliumforlong periods. Thus, even though macrophages serve as a frwst line ofdefenseforthe alveolar
surface, they may also be capable of injuring the host while exercising their defensive role.
Introduction
Pulmonary macrophages are important since their
migratory patterns, phagocytic behavior, and
secretory potential are often pivotal events in the
pathogenesis ofpulmonary disease. Theirprotective
role iswidely appreciated and ourunderstandingofit
growing. Even though macrophages are the first line
of defense for the airway and alveolar surfaces, we
believe that they can also injure the host while ex-
ercisingtheirdefensive roles. This reviewwillbriefly
summarize both classical and more recent aspects of
the protective posture of pulmonary macrophages
and then will describe accumulating evidence that
macrophages also play a part in the pathogenesis of
pulmonary diseases.
The respiratory tract is the most common route for
entry of toxic particles from modem urban and oc-
cupational environments. The same thinness and
delicacy of the air-blood barrier which allows rapid
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exchange ofoxygen and carbon dioxide also reduces
its effectiveness as a barrier to inhaled carcinogens,
toxic particles, allergens, noxious gases, and micro-
organisms. Growing evidence suggests that most
pulmonary diseases are eitherinitiatedby, oratleast
aggravated by, the inhalation ofparticles and gases
and that the role of environmental factors in the
development of respiratory disease is important.
First, we will describe briefly the positive contribu-
tions of pulmonary macrophages.
Helpful Effects of Macrophage
Function
Macrophages are usually credited with keeping
the alveolar surfaces clean and sterile. They ingest
inhaled particles and pathogens as well as endoge-
nous effete cells and even "worn-out" surfactant.
Alveolar macrophages are large, mononuclear,
phagocytic cells found on the alveolar surface. They
do not form part of the continuous epithelial layer,
which is made up of pulmonary surface epithelial
cells (type I pneumonocytes) and greatalveolarcells
21(type II pneumonocytes). Rather the alveolar mac-
rophages rest on this lining. Considerable interest
still exists in the origin and kinetics of pulmonary
macrophages. A primary question is whether they
are normally derived directly from bone marrow via
the blood monocytes or from an intrapulmonary
population of macrophages and precursors capable
ofself-replication. Several investigators suggestthat
both pathways can occur, depending on the condi-
tions. Alveolar macrophages are ultimately derived
from cells in the bone marrow; however, a resident
population in the lungs can be maintained by secon-
dary cell renewal systems within the lung.
Thus, there are multiple overlapping strategies for
maintaining the macrophage population. In normal
unchallenged animals, the immediate precursors are
supplied by a cell renewal system in the pulmonary
interstitium. Division of existing alveolar macro-
phages mayalsocontribute tothe maintenance ofthe
pool offree cells. Demand for more macrophages, as
a result ofinfection or large numbers ofinhaled par-
ticles, may be metby increased multiplication offree
macrophages, release of pre-existing cells from
reservoirs within the lungs, increased production
frommacrophage precursors inthelunginterstitium,
and increased flux of monocytes from the blood to
the lung.
Pulmonary macrophages are largely responsible
for the normal sterility of the lung (1) and for pro-
tecting the respiratory tract against awide variety of
foreign materials (24). Their phagocytic and lytic
potentials provide most of the known bactericidal
properties of the lungs. During acute infection or
injury they are also supplemented by other leuko-
cytes. Increased inert or infectious particles stimu-
late the recruitment ofadditional macrophages. Like
other phagocytes, alveolar macrophages are rich in
lysosomes, subcellular organelles 0.5 ,m or less in
diameter(5). Thelysosomes attachthemselves tothe
phagosomal membrane surrounding the ingested
pathogen. Then the lysosomal and phagosomal
membranes become continuous and the lytic en-
zymes kill and digest the bacteria. Among the en-
zymes known to be present in lysosomes are pro-
teases (5), acid ribonuclease (6),,/-glucuronidase (7),
acid phosphatase (6, 7), lysozyme (8), f8-galacto-
sidase (9), and phospholipases (10).
Not only do pulmonary macrophages ingest and
kill pathogens butthey also deal decisively with non-
living, insolubledustand debris. Thisfunction isalso
essential, since rapid endocytosis ofinsoluble parti-
cles prevents particle penetration through the al-
veolar epithelia and facilitates alveolar-bronchiolar
transport. Schiller (11) and, later, Sorokin and Brain
(12) found little evidence that macrophages laden
with dust can re-enter the alveolar wall; only free
particles appear to penetrate. Thus phagocytosis
plays an important role in the prevention of particle
entry into the fixed tissues of the lung. If particles
leave the alveolar surface and penetrate the tissues
subjacent to the air-liquid interface (type I and II
cells, interstitial and lymphatic tissues), their re-
moval is slowed. Those remaining on the surface are
cleared with a biological half-time estimated to be
24 hrin humans, whileparticlesthat have penetrated
into "fixed" tissues are cleared with half-times
ranging from a few days to thousands of days.
Therefore, the extent to which macrophages influ-
ence the probability ofparticle penetration intofixed
tissues is critical in determining the clearance times
ofparticlesfromthe nonciliated regionsofthelungs.
The re-entry of alveolar macrophages into lym-
phatic pathways and connective tissue has often
been suggested but rarely observed. Some inves-
tigators consider the presence ofparticle-containing
macrophages in these compartments to be compel-
ling evidence. However, distinguishing between the
entry ofalveolar macrophages and the entry ofbare
particles which are subsequently ingested by con-
nective tissue macrophages already present is dif-
ficult. During alveolar clearance, some noningested
particles may follow lymphatic or vascular channels
from alveoli into the peribronchial, perivascular, or
subpleural adventitiae and thus penetrate the con-
nective tissue of the lung. They are then stored by
resident macrophages. This pathway may be more
common when conditions favor increased lymphatic
permeability (e.g., pulmonary edema).
Evidence is rapidly accumulating to indicate that
macrophages have roles besides phagocytosis. The
diverse activities of pulmonary macrophages which
relate them to other cells and processes are being
increasingly recognized (13). They are involved in
both host defense and host-damaging reactions. The
available data show that both outcomes are possible,
but predictingandcontrollingthese reactions remain
difficult. Beyond that, they secrete a variety ofsub-
stances which interact with multi-enzyme cascades
and other cells such as lymphocytes, fibroblasts and
other macrophages. As will be discussed later, some
ofthese secretions are involved in connective tissue
turnover, e.g., collagenase, elastase, and lysosomal
enzymes; others affect lymphoid cells by helping to
regulate mitogenesis and differentiation. Macro-
phages release additional products such as inter-
feron, lysozyme, and certain components of com-
plement that are involved in defense processes.
Other biologically active materials secreted by
macrophages include an angiogenesis factor, plas-
minogen activator, prostaglandins, nucleosides,
cyclic nucleotides, pyrogens, granulopoietins, and
factorsinfluencingfibroblast proliferation and tumor
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enzyme systems such as the clotting, complement,
fibrinolytic, and kinin-generating system.
Pulmonary macrophages are also involved in the
induction and expression of several forms of cell-
mediated and humoral immunity; they are essential
for delayed hypersensitivity reactions, and may be
involved in allograft rejection and the pathogenesis
of autoimmune diseases. The response of macro-
phages in the lung to antigens in the respiratory tract
may vary. They may prevent excessive antigen
stimulation by ingesting and catabolizing inhaled
foreign proteins and antigens derived from bacteria,
viruses, fungi, and other microbes. Alternatively,
they may preserve and present antigens to lympho-
cytes and act cooperatively with components of the
immune system.
Their observed potential for recognizing and de-
stroying neoplastic cells, thus preventing the de-
velopmentofcancer, is anotherremarkable property
that merits further study (14). More than two
decades ago, Gorer (15) noted that macrophages
were prominent during the rejection of tumor cells.
Since then, other investigators (16, 17) have shown
that macrophages can selectively damage tumor
cells. The stimulation of macrophages by infection
can further enhance the ability of macrophages to
prevent tumor growth (18, 19).
This growing list of macrophage properties and
functions suggests that macrophages are much more
than residentgarbage men. Continued exploration of
these functions is required to appreciate better the
biologic potential ofpulmonary macrophages and to
gain insight into when they help or hurt us.
Harmful Effects of Macrophage
Function
In addition to a variety of protective postures
which help the host, macrophages may also be par-
ticipants in the pathogenesis oflung disease. We will
begin by considering how theirnormal behavior may
occasionally have untoward effects. We will then
consider other types of responses that may involve
damage or unusual events. The normal activity and
movement of pulmonary macrophages may cause
harm. Because the macrophages are actively phago-
cytic, inhaled toxic, radioactive, or carcinogeneic
particles become concentrated within pulmonary
macrophages. Whatbegins as adiffuse andrelatively
even exposure becomes highly localized and non-
uniform. "Hot spots" of high dosage are formed
which may exceed the thresholds for certain effects
and cause damage.
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Similarly, in the airways adherence of macro-
phages to the epithelium may increase epithelial ex-
posure toinhaled toxic materials. More importantly,
perhaps, this close association with the bronchial
epithelium can lead to transbronchial transport of
inhaled particles and subsequent reingestion by sub-
epithelialconnective tissue macrophages (20). These
cells, like their relatives in the alveolar and airway
compartments, also segregate, retain, and perhaps
metabolize carcinogenic and other toxic particles.
"Hot spots" may also be associated with damage
and perhaps with enhanced epithelial transport.
These, in turn, lead to increased access of toxic
particles to the connective tissue compartment. Al-
veolar epithelial defenses may also be breached at
the alveolar level, but because of lymphatic path-
ways, particles may end up in similar sites. Particles
gaining access to the lymphatics are probably
cleared slowly and thus they may attain great signifi-
cance in the pathogenesis of many lung diseases.
Months and years after exposure to particles, these
connective tissue burdens may constitute the major
reservoir of retained particles. In addition, connec-
tive tissue macrophages may contribute to progres-
sive damage by concentrating and storing potent
toxic particles for long periods.
Another way in which macrophages may be in-
volved is through diminution or failure of their de-
fensive role. Anumberofinvestigators, usingbothin
vivo or in vitro bactericidal or phagocytic assays,
have shown that macrophage function can be com-
promised by environmental insults and pathological
changes. Such diverse agents as silica, immunosup-
pressives, ethanol intoxication, cigarette smoke, air
pollution, and oxygen toxicity, can dramatically de-
press the ability of pulmonary macrophages to pro-
tect their host. Sometimes the agent or factor acts
directly on the macrophage producing a damaged or
even a dead cell. In other cases (e.g., high concen-
trations of inhaled particles) the mechanism can be
competitive inhibition in which the phagocytic
machinery becomes saturated even in the absence of
cytotoxicity. In other instances, particularly those
situations involving pulmonary edema or altered
acid-base balance, the macrophages may be undam-
aged, but their activity may be depressed because of
an indirect effect on their milieu, the airway, or al-
veolar microenvironment. Nonetheless, it is impor-
tant to realize that macrophage failure or damage is
not always a cause of the disease in question; in
many instances, alterations in macrophage function
may simply reflect the onset and progression ofthe
disease. For example, changes in macrophage activ-
ity during pulmonary edema associated with oxygen
toxicity fall in this class. It is not the macrophage's
failure to ingest particles or bacteria which causes
23the edema; rather the reverse. Many investigators
have similarly misinterpreted associations between
other altered respiratory defense mechanisms and
lung disease. For example, the presence of altered
mucociliary transportinlungdisease does not neces-
sarily imply that depressed mucociliary transport
hascaused the lungdisease orevencontributed to its
pathogenesis. Defective mucus movement may be a
result of the disease rather than a cause. Carefully
designed experiments are needed to make these dis-
tinctions.
Macrophage Damage and Pulmonary
Connective Tissue: Proteolysis
There are situations in which pulmonary mac-
rophages not only fail but are directly implicated in
the pathogenesis of pulmonary diseases. Two im-
portant examples both involve pulmonary connec-
tivetissue (21, 22). Connective tissue proteins have a
fundamental role in lung structure and function.
Collagen and elastin help maintain alveolar, airway
and vascular stability, limit lung expansion and con-
tribute to lung recoil at all lung volumes. Elastin
makes the major contribution to the lung's mechani-
cal properties at low and middle lung volumes and
also helps to tether and orient collagen fibers.
Changes in elastin and collagen architecture result
ultimately in small airway obstruction by decreasing
the elasticity ofstructures supportingtheconducting
airways. Other associated inflammatory changes re-
sult in plugging, narrowing, and obliteration ofsmall
airways. Changes can be observed in the lumen as
well as in the epithelial walls. Two groups of lung
disease are associated with aberrations of normal
collagen and elastin balance: emphysematous and
fibrotic disorders. To what extentthese associations
involve changes in the rate and nature of synthesis,
or ofdegradation ofthese proteins remains specula-
tive. Let us first review the relationship of macro-
phages to proteolysis.
Growing understanding of the pathogenesis of
emphysema hasfocused attention onthe natural bal-
ance between elastase and antielastase which exists
in the respiratory tract. Elastase is one of many
lysosomal and cytoplasmic enzymes involved in the
intracellular killing and digestion of pathogens. Al-
though these enzymes constitute an important as-
pect ofthe lung's defensive posture, when kept in a
chronically activated state, their digestive capacity
may damage pulmonary tissues. Release of lyso-
somal enzymes, particularly proteases, from acti-
vated macrophages and leukocytes promote the
development of emphysema. Release occurs as a
consequence ofcelldeath, cell injury, exocytosis, or
regurgitation while feeding. Increased deposition of
inert or infectious particles acts to recruit additional
macrophages and thus the effect may be reinforced.
Interest in proteolytic injury was stimulated be-
cause of knowledge about pulmonary emphysema
associated with inborn al-antitrypsin-inhibitor defi-
ciency in humans (23). Imbalances between pro-
teolytic activity and its control or inhibition have
important implications as a generalized mechanism
oflung injury in other pulmonary pathological states
caused by air pollution, or the inhalation ofoccupa-
tional dusts.
Macrophages secrete enzymes capable of con-
nective tissue degradation. Both collagenase and
elastase activity can be detected in fluids from mac-
rophage cultures (24-26). The release of both en-
zymes is influenced by activation and is greaterfrom
exudative peritoneal macrophages than from resi-
dent peritoneal macrophages; it is also stimulated by
phagocytosis. Enzyme secretion is stimulated by
cytochalasin B, colchicine, and vinblastine. The
epidemiological and clinical relationships between
smoking and chronic obstructive pulmonary disease
are probably mediated by release of elastase from
macrophages and neutrophils. There isalsoevidence
that exposure to smoke causes increased synthesis
and release of elastolytic enzymes from these cells
(27, 28). Importantly, culture media from alveolar
macrophages of smokers demonstrated greater
elastase activity than those obtained from non-
smokers. These findings tend to confirm the sus-
pected role of PM in the pathogenesis ofpulmonary
emphysema in smokers.
Smokes and other pollutant particles character-
istic of work and urban environments also act to
recruit more cells, to activate them, and to release
proteolytic enzymes. Macrophages and polymor-
phonuclear leukocytes may then be centrally
involved in many stages of the development of pul-
monary disease. Oxidant radicals produced by
macrophages and neutrophils may also be involved.
These highly reactive oxygen byproducts may dam-
age lung tissue directly; they may also have an indi-
rect effect by damaging macrophages which sub-
sequently release toxic or proteolytic enzymes. The
extent of damage in the latter case depends on the
number ofadditional macrophages recruited, on the
extent oftheiractivation, and on the degree to which
elastase, oxidants, and other materials are secreted
or released from macrophages. Pathogenesis ofem-
physema may also involve damage to the epithelium
which provides greater access of elastase to the
elastin.
A number of animal models have been produced
which supportthe proteolytic theory ofemphysema.
A lesion very similarto emphysemacan be produced
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specific proteolytic enzymes such as papain or by
elastase (29-30). Homogenates of neutrophils or
pulmonary macrophages have a similar effect
(32, 33) as does elastase present in purulent sputum
(34, 35). A number of investigators have described
the anatomical and physiological development of
emphysematouslike lesions following intratracheal
instillation of elastase. Generally, the lesion is
characterized by aninitial phase ofenzymatic degra-
dation of elastin in the lung followed by a more
gradual architectural derangement characterized by
expanded airspaces and/or destruction of some al-
veolar units. The relationship between relatively
short-term animal models where the lesion develops
in a matter of weeks and the human disease which
requires 10 to 40 years is still a mystery.
The role ofa-i-antitrypsin in man has emphasized
the importance of not only proteases but also anti-
proteases. When porcine pancreatic elastase is in-
stilled into hamsters with no serum or with serum
from a-i-antitrypsin-deficient people, the result is a
lesion resembling emphysema. However, when
identical amounts of pancreatic elastase are added
with serum from normal individuals, no change oc-
curs. Thus the maintenance of a normal balance be-
tween elastase and elastase inhibitors is critical. The
body's defenses against excessive elastase levels in-
clude inhibitors present in alveolar andairway lining
fluid and the ingestion and degradation ofelastase by
macrophages. It is not known to what extent these
antiprotease inhibitors are derived locally and sys-
temically.
There maybechanges inotherinhibitors. Changes
inthe composition ofthe lungfluid inthe interstitium
may be important. The concentration of antipro-
teases at the site of injury may be changed and may
be unrelated to those measured in the serum or even
the lavage fluid. In any event, akey eventappears to
be disruption of the natural elastase-antielastase
homeostasis may reflect increased protease and/or
decreased inhibitor activity, resulting in a sustained
burden of unopposed proteases and destruction of
alveolar structures.
Therapies should focus on the reduction of unop-
posed proteases. They could attempt either to regu-
late the production and release of neutrophil and
macrophage proteases orto augment inhibitor activ-
ity by stimulating endogenous production through
the use of synthetic antielastase agents, or through
replacement therapy utilizing elastase recovered
from blood orotherbiological fluids. Further studies
are needed to examine mechanisms of release of
proteolytic enzymes, their effects on lung cells and
tissues, and the protection afforded by serum and
lung antiproteases.
Macrophage Damage and Pulmonary
Connective Tissue: Fibrogenesis
Dead or dying macrophages may release sub-
stance(s) which can attract fibroblasts and elicit
fibrogenic responses. Dust particles of appropriate
size, shape, chemical composition, and durability,
may deposit on alveolar surfaces and stimulate pro-
ductionofexcess collageninthe alveolarmembrane.
In such fibrotic diseases as asbestosis and silicosis,
progressivefibrogenesis may continue long afterthe
exposure to dust particles has stopped. Excessive
collagen may make the lungs stiffer than normal,
severely decreasing the vital capacity and increasing
the muscular forces required for breathing.
Asbestos, glass, and other fibrous dusts all have
been shown to stimulate collagen synthesis (36, 37).
Fibers over 5 um in length are sometimes incom-
pletelyingestedbymacrophages (38)and mayleadto
macrophage death or release of mediators. Growth
of fibroblasts in vitro has been shown to require a
solid supporting particle ofcritical minimum dimen-
sions (39).
There is some evidence that fibrogenesis may in-
volve macrophages and occur as a two-step process
(40, 41). This especially applies to highly fibrogenic
particles such as silica which have very symmetrical
shapes. Silica has not been shown to exert a direct
stimulatory effect on fibroblasts. Rather, the inter-
action of a particle with a macrophage is thought to
release factors which stimulate local production of
collagen by fibroblasts. It is unlikely that macro-
phages differentiate into collagen-synthesizing
fibroblasts (42, 43) and the addition of silica to cul-
tured fibroblasts does not stimulate collagen
biosynthesis or release (37).
A number of investigators have produced evi-
dence showing that macrophages can produce a
factor or factors which, in turn, influence the prolif-
eration (44) and biosynthetic activity (45) of fibro-
blasts. After adding silica particles to mouse macro-
phages, Heppleston and Styles (40) reported the
presence of a factor which stimulated chick fibro-
blasts to produce collagen. Using rabbit pulmonary
macrophages and WI-38 fibroblasts, Burrel and An-
derson (46) showed the same response. More re-
cently, Allison (47) summarized other experiments
carriedoutinhislaboratory supportingthetwo-stage
theory of fibrogenesis utilizing an in vivo prepara-
tion.
Diffusion chambers bounded by Millipore filters
were placed in the peritoneal cavities of mice for a
month or more. If the chambers contained only
peritoneal macrophages or silica particles, no fibro-
genesis occurred. But if both silica and peritoneal
macrophages were placed in the chamber, the result
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pleura with significant collagen deposition beneath
the mesothelial cells. Allison (47) concluded that "a
factor released from surviving macrophages stimu-
lated by silica passes out of the diffusion chamber
and stimulates collagen synthesis by fibroblasts."
Silica and asbestos present an added hazard of
being cytotoxic to alveolar macrophages. Within a
few minutes they can lyse cells by direct interaction
with the plasma membrane, or if successfully in-
gested, in several hours cause rupture of secondary
lysosomes, releasing lysosomal hydrolases into the
cytoplasm (41). The resulting deadmacrophages can
become focal points for further fibrogenesis. In
addition, the particles are released anew on the al-
veolar surface to cause more irritation. Not all pub-
lished experiments, however, support the two-stage
theory. Harrington et al. (48) added culture medium
from hamster macrophages incubated with silicaand
observed decreased collagen biosynthesis. Addi-
tional research is needed to explore these possible
species differences. To understand fibrosis, the role
of lymphocytes, macrophages, fibroblasts, and the
effect of fibrogenic agents on collagen balance and
on the replication and differentiation ofeach paren-
chymal cell type need to be studied (49).
Other Effects
The responses ofthe lung to inhaled antigens and
allergens and the area of environmental allergic re-
spiratory disease is also emerging as an important
area which may involve macrophages. Considerable
evidence is available which shows that inhaled or-
ganic chemicals, dusts, molds, and animal proteins
can cause avariety oflung responses such as allergic
asthma, extrinsic allergic alveolitis, immune com-
plex disease and other phenomena. Since excellent
discussions of these diseases are available (50), we
will not review them here except to point out that
macrophages may sometimes be involved. Little is
known about the degradation of proteins deposited
on the respiratory tract surfaces. No doubt, in many
instances macrophages and pulmonary clearance
defend the bodyagainst excessive antigenic stimula-
tion. However, there may also be circumstances
when clearance pathways cooperate with the im-
mune system andpreserve andpresentimmunogenic
molecules to the immune system. Thus the issue of
how and when pulmonary macrophages suppress or
enhance the immunogenicity of antigens must be
confronted.
Other pulmonary diseases may also involve mac-
rophages. Pulmonary-alveolar proteinosis, adisease
characterized by the presence of lipoproteinaceous
material in the alveoli, may alter macrophage func-
tion (3, 4). Golde et al. (51) have suggested that
phagocytosis of excessive quantities of the charac-
teristic lipoproteinaceous material may damage
macrophages and contribute to the frequent infec-
tious complications of this disease. Gee et al. (52)
have speculated on possible relationships between
sarcoidosis and macrophages. They noted that the
disease is often associated with elevations ofserum
levels of lysozyme or angiotensin-converting en-
zyme or both. They believe that the elevated lyso-
zyme levels are caused by increased secretion ofthe
enzyme by monocytes and lung macrophages. In
addition, human pulmonary macrophages recovered
from patients with sarcoid have more angiotensin-
converted enzyme than in those recovered from
normals. They believe there is evidence for macro-
phage activation in sarcoidosis.
Conclusion
Thus, even though macrophages serve as a first
line ofdefenseforthe alveolarsurface, theymay also
be capable ofinjuring the host while exercising their
defensive role. Supportforstudyingthe effects ofair
pollutiononmacrophages shouldbecontinued. Such
studies are essential in determining mechanisms of
biological response and as part ofsystematic studies
ofdose-response relationships. Systematicexposure
of animals to materials produced by technological
advance followed by evaluation of macrophage
function or damage will permit assessment of some
of the effects of these materials. Additional knowl-
edge is needed about the ultrastructural and bio-
chemical alterations in alveolar macrophages
following exposure to physical, chemical, and infec-
tious agents. The effects of parameters which may
modulate the pulmonary response to atmospheric
and industrial contaminants should be measured.
The effects of altered physiological states and con-
current illness should be systematically explored.
Frequently, important contributions to our under-
standing of environmental disease have depended
upon the existence of appropriate animal models.
These investigations were supported by grant No. EPA-
RA05091 from the Environmental Protection Agency and bygrant
No. HL 19170 from the National Heart, Lung, and Blood Insti-
tute.
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